FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

The FibroGen – AstraZeneca China Agreement for Roxadustat remains in place

FibroGen to explore licensing opportunities for Roxadustat

SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ:FGEN) announced today that FibroGen and AstraZeneca have agreed to terminate the U.S./RoW roxadustat collaboration agreement entered into on July 30, 2013, under which AstraZeneca held development and commercialization rights in the United States and other territories outside of China not licensed to Astellas Pharma Inc. Pursuant to a termination and transition agreement entered into between the parties, AstraZeneca is returning all U.S./RoW roxadustat rights to FibroGen (with the exception of South Korea) and providing certain assistance during a transition period. FibroGen’s collaboration agreement with AstraZeneca for roxadustat in China remains in place and roxadustat remains the leader in China by brand value share in the chronic kidney disease (CKD) anemia category. In the event FibroGen subsequently monetizes or commercializes roxadustat in the territories formerly licensed under the U.S./RoW collaboration agreement, FibroGen will have certain financial obligations to AstraZeneca.

“We continue to believe that roxadustat represents an important potential therapy for patients in the U.S. and other territories where it has not yet been approved,” said Thane Wettig, FibroGen Chief Executive Officer. “Based on the data presented at ASH 2023 investigating roxadustat for the treatment of anemia in patients with higher transfusion burden low-risk-MDS, we will be evaluating opportunities to bring this innovative medicine …

Full story available on Benzinga.com